Rohto Pharmaceutical Co.,Ltd.
4527.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | ¥309 | ¥271 | ¥239 | ¥200 |
| % Growth | 14% | 13.5% | 19.5% | – |
| Cost of Goods Sold | ¥139 | ¥114 | ¥101 | ¥83 |
| Gross Profit | ¥169 | ¥157 | ¥137 | ¥116 |
| % Margin | 54.9% | 58.1% | 57.6% | 58.3% |
| R&D Expenses | ¥15 | ¥12 | ¥11 | ¥9 |
| G&A Expenses | ¥58 | ¥47 | ¥44 | ¥39 |
| SG&A Expenses | ¥116 | ¥101 | ¥90 | ¥77 |
| Sales & Mktg Exp. | ¥58 | ¥54 | ¥46 | ¥38 |
| Other Operating Expenses | ¥0 | ¥4 | ¥2 | ¥1 |
| Operating Expenses | ¥131 | ¥117 | ¥103 | ¥87 |
| Operating Income | ¥38 | ¥40 | ¥34 | ¥29 |
| % Margin | 12.5% | 14.8% | 14.2% | 14.7% |
| Other Income/Exp. Net | ¥3 | ¥1 | ¥0 | -¥1 |
| Pre-Tax Income | ¥42 | ¥42 | ¥34 | ¥28 |
| Tax Expense | ¥11 | ¥10 | ¥8 | ¥7 |
| Net Income | ¥31 | ¥31 | ¥26 | ¥21 |
| % Margin | 10% | 11.4% | 11.1% | 10.6% |
| EPS | 136.11 | 135.6 | 115.62 | 92.61 |
| % Growth | 0.4% | 17.3% | 24.8% | – |
| EPS Diluted | 135.46 | 135.21 | 115.29 | 92.34 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥1 | ¥2 | ¥1 | ¥0 |
| Interest Expense | ¥1 | ¥0 | ¥0 | ¥0 |
| Depreciation & Amortization | ¥13 | ¥9 | ¥8 | ¥8 |
| EBITDA | ¥56 | ¥50 | ¥42 | ¥36 |
| % Margin | 18.3% | 18.6% | 17.7% | 17.9% |